Combination of membrane bioreactor with chemical coagulation for the treatment of real pharmaceutical wastewater: Comparison of simultaneous and consecutive pre-treatment of coagulation on MBR performance

In this work, the combination of the coagulation process with the MBR system to reclaim effluent in pharmaceutical industries was investigated. In this research, comparison/concentration optimization of two modes of integrations, including simultaneous; one-step one pot, and consecutive coagulation MBR were investigated. Results showed that COD removal in simultaneous and consecutive modes at optimum values were 85 % and 95.8 %, respectively, which were considerably higher than that of control MBR; 53.89 %. The total fouling ratio for control MBR, simultaneous, and consecutive modes at optimum conditions were 70.69 %, 37.3 %, and 42.5 %, respectively, confirming that the integrated coagulation process and MBR system were considerably effective. Analyzing the secreted metabolite, e.g. protein, carbohydrate, and LB/TB-EPS ratio in the MBR tank as well as on the membrane surface showed that the charge-neutralization and entrapment of bio-foulants by aggregated clots during the coagulation hinder the adhesion of the biofouling agents on the membrane surface, therefore in-line with the flux attenuation trend, lower metabolite concentration results in less membrane fouling. It was found that simultaneous coagulative MBR with 100 mg/L FeCl3 concentration demonstrates better fouling mitigation in comparison with consecutive (even with poly aluminum chloride; PACl as coagulant aid) MBR, while the latter mode shows better performance in terms of wastewater treatment. These findings open avenues for future techno-economic assessments of a coagulation-assisted MBR, providing a cost-effective solution for treating high-strength wastewater on a larger scale.